The impact of COVID-19 epidemic on tuberculosis control in Kashgar of Xinjiang Uygur Autonomous Region

doi:10.3969/j.issn.2096-8493.20210071

Abstract

Abstract:

Objective Explore the impact of COVID-19 epidemic on tuberculosis (TB) control and prevention in Kashgar, and provide scientific basis for formulating corresponding prevention and control strategies. Methods TB registration and sputum examination at the end of 2nd month and at the end of treatment were compared between 2020 and 2019 based on the routine surveillance from TB Information Management System which is the subsystem of the “China Disease Prevention and Control Information System”, to explore the potential impact of COVID-19 epidemic on TB control and prevention. Results The number of registered TB patients in Kashgar in 2020 was 11159, a decrease of 7504 from the number of registered 18663 patients in 2019. The average daily number of registrations decreased from 51 in 2019 to 31 in 2020, a decrease of 39.22%. In 2020, the number of TB patients who required sputum examination at the end of second month of treatment was 28419, and 17715 patients can perform sputum examination within 7 days, the sputum examination rate is 62.34%, which was significantly lower than the 67.45% in 2019 (7894/11703) (χ ²=94.04, P<0.05). In 2020, the number of TB patients who required sputum examination at the end of treatment was 12816, and 5205 patients can perform sputum examination within 7 days, the sputum examination rate was 40.61%, which was significantly lower than the 42.24% (17370/41124) (χ ²=10.60, P<0.05) in 2019. Conclusion The COVID-19 epidemic has a certain impact on the TB control and prevention in Kashgar in the short term, this lead to a decrease in the number of TB patient discovery and in the rate of timely follow-up for sputum examination.

Key words: Tuberculosis, COVID-19, Disease outbreak and prevalent, Infectious disease control, Comprehensive prevention, New evaluation, Xinjiang

Xirizhati ·Mamut, Maiweilanjiang ·Abulimiti, Diermulati ·Tusun, Gulimina ·Abulimiti, LIU Zhen-jiang, LI Guan-zhen, Liwayiding ·Aersila, HUANG Fei, ZHAO Yan-lin, ZHANG Li-jie, OU Xi-chao. The impact of COVID-19 epidemic on tuberculosis control in Kashgar of Xinjiang Uygur Autonomous Region[J]. Journal of Tuberculosis and Lung Disease , 2021, 2(3): 234-238. doi: 10.3969/j.issn.2096-8493.20210071

Figures/Tables 4

References 10

[1]	Diermulati Tusun, Maiweilanjiang Abulimiti, Xirizhati Mamuti, et al. The Epidemiological Characteristics of Pulmonary Tuberculosis-Kashgar Prefecture, Xinjiang Uygur Autonomous Region, China, 2011—2020. China CDC Weekly, 2021, 3(26):557-561. doi: 10.46234/ccdcw2021.144. doi: 10.46234/ccdcw2021.144 URL
[2]	Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science, 2020, 368(6491):638-642. doi: 10.1126/science.abb6105. doi: 10.1126/science.abb6105 URL
[3]	Fei H, Yinyin X, Hui C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020, 3:100032. doi: 10.1016/j.lanwpc.2020.100032. doi: 10.1016/j.lanwpc.2020.100032
[4]	Wu Z, Chen J, Xia Z, et al. Impact of the COVID-19 pandemic on the detection of TB in Shanghai, China. Int J Tuberc Lung Dis, 2020, 24(10):1122-1124. doi: 10.5588/ijtld.20.0539. doi: 10.5588/ijtld.20.0539 URL
[5]	Liu Q, Lu P, Shen Y, et al. Collateral Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Tuberculosis Control in Jiangsu Province, China. Clin Infect Dis., 2021, 73(3):542-544. doi: 10.1093/cid/ciaa1289. doi: 10.1093/cid/ciaa1289 URL
[6]	McQuaid CF, McCreesh N, Read JM, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J, 2020, 56(2):2001718. doi: 10.1183/13993003. doi: 10.1183/13993003 URL
[7]	沈鑫, 沙巍, 刘剑君. 新型冠状病毒肺炎疫情对结核病防控的影响及对策. 中国防痨杂志, 2020, 42(6):544-548. doi: 10.3969/j.issn.1000-6621.2020.06.003. doi: 10.3969/j.issn.1000-6621.2020.06.003
[8]	金锋. 新冠肺炎疫情洗礼的中国应做终结结核病的排头兵. 中国防痨杂志, 2021, 43(3):197-200. doi: 10.3969/j.issn.1000-6621.2021.03.001. doi: 10.3969/j.issn.1000-6621.2021.03.001
[9]	肖和平, 刘一典. 新型冠状病毒肺炎疫情防控机制对结核病防治的启示. 中国防痨杂志, 2020, 42(4):311-315. doi: 10.3969/j.issn.1000-6621.2020.04.003. doi: 10.3969/j.issn.1000-6621.2020.04.003
[10]	Xia Yy, Huang F, Chen Hui, et al. The Impact of COVID-19 on Tuberculosis Patients’ Behavior of Seeking Medical Care—China, 2020. China CDC Weekly, 2021, 3(26):553-556. doi: 10.46234/ccdcw2021.143. doi: 10.46234/ccdcw2021.143 URL

时间段	起止时间	时间(d)
第1次非管控期	2020年1月1日至1月24日	24
第1次管控期	2020年1月25日至3月4日	40
第2次非管控期	2020年3月5日至7月15日	133
第2次管控期	2020年7月16日至9月2日	49
第3次非管控期	2020年9月3日至10月23日	51
第3次管控期	2020年10月24日至11月22日	30
第4次非管控期	2020年11月23日至12月30日	38

时间段	2020年肺结核登记		2019年肺结核登记		登记例数下降幅度(%)
时间段	例数	日均例数	例数	日均例数	登记例数下降幅度(%)
第1次非管控期	393	16	2480	103	84.47
第1次管控期	379	9	2191	55	83.64
第2次非管控期	9261	70	11087	83	15.66
第2次管控期	349	7	994	20	65.00
第3次非管控期	403	8	886	17	52.94
第3次管控期	179	6	488	16	62.50
第4次非管控期	195	5	537	14	64.29
合计	11159	31	18663	51	39.22

时间段	2020年			2019年			χ²值	P值
时间段	应查痰例数	7d内查痰例数	查痰率 (%)	应查痰例数	7d内查痰例数	查痰率 (%)	χ²值	P值
第1次非管控期	360	221	61.39	4345	2330	53.62	8.074	0.005
第1次管控期	556	290	52.16	6718	3771	56.13	3.289	0.070
第2次非管控期	5781	4229	73.15	8541	5689	66.61	69.359	<0.001
第2次管控期	3978	2495	62.72	6576	4488	68.25	33.836	<0.001
第3次非管控期	532	380	71.43	1051	680	64.70	7.228	0.007
第3次管控期	191	100	52.36	518	335	64.67	8.927	0.003
第4次非管控期	305	179	58.69	670	422	62.99	1.636	0.201
合计	28419	17715	62.34	11703	7894	67.45	94.036	<0.001

时间段	2020年			2019年			χ²值	P值
时间段	应查痰例数	7d内查痰例数	查痰率 (%)	应查痰例数	7d内查痰例数	查痰率 (%)	χ²值	P值
第1次非管控期	668	199	29.79	1501	733	48.83	68.412	<0.001
第1次管控期	1719	385	22.40	4063	1904	46.86	302.311	<0.001
第2次非管控期	2131	742	34.82	20637	7985	38.69	12.259	0.001
第2次管控期	520	146	28.08	4603	1306	28.37	0.020	0.887
第3次非管控期	1491	870	58.35	2875	1293	44.97	70.274	<0.001
第3次管控期	2828	1263	44.66	2115	897	42.41	2.488	0.115
第4次非管控期	3459	1600	46.26	5330	3252	61.01	184.725	<0.001
合计	12816	5205	40.61	41124	17370	42.24	10.600	0.001

[1]	Chinese Antituberculosis Association. Expert consensus on diagnosis and prevention of inactive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 197-201.
[2]	XU Jing, LUO Ping, HE Xiao-xin. Analysis of characteristics and diagnosis delay of 629 elderly tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 216-222.
[3]	SONG Yi-yan, CHEN Jie, LI Fang-hua, LI Ruo-nan, ZHAO Jing, YU Da-wei, SONG Hua-feng, XU Jun-chi, WU Min-juan, XU Ping. Analysis of 44 drug resistance patients with tuberculosis and received repeated treatment [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 239-242.
[4]	GUAN Fu-yuan, CHEN Zhi-hao, LI Wen-hui, YE Xiao-hua, ZHONG Xin-guang. Characteristics analysis of diagnosis delay among elderly tuberculosis patients in Dongguan City from 2009 to 2018 [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 243-250.
[5]	FENG Xin, HU Yan, SHEN Jing, ZHAN Jian. Analysis of Mycobacterium tuberculosis drug resistance in drug-resistance monitoring sites in Chongqing Municipality (2014-2019) [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 251-255.
[6]	LI Jing, ZHANG Yan, WU Qian-hong. Research progress on free DNA detection of Mycobacterium tuberculosis of non-sputum samples in tuberculosis diagnosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 277-282.
[7]	JIANG You-li, ZHANG Pei-ze, DENG Guo -fang, CHEN Jing-fang. Research progress of delay in diagnosis of tuberculosis and its influencing factors [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(3): 289-293.
[8]	ZHOU Bi-xia, YUAN Gong-ling, ZENG Ling-wu, ZHU Yi, CHENG Xi, LI Min, WU Mei-ying. Comparative analysis of CT signs of Mycobacterium kansasii pulmonary disease and pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 125-130.
[9]	ZHOU Ling-yun, LIANG Da-bin, LI Juan, HUANG Min-ying, ZHAO Jin-ming, LIANG Xiao-Yan. Analysis of epidemiological characteristics of tuberculosis in schools in Guangxi from 2017 to 2019 [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 144-149.
[10]	LI Ya-min, GAO Zhi-dong, ZHAO Xin. Analysis on the operation of tuberculosis automated-alert system in schools in Beijing [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 150-155.
[11]	ZHONG Tao, WU Li-juan, FAN Yu-zheng, GUO Xu-jun, Wang Jian, LIU Sheng-yuan. Knowledge, attitude and practice towards tuberculosis prevention and control among elderly people in Nanshan district, Shenzhen: a cross-sectional study [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 156-163.
[12]	ZHANG Hong-wei, SUN Shan-hua, GAO Zhi-dong, XU Yan, TAO Li-ying, CHEN Xi. Treatment and outcomes of rifampicin-resistant pulmonary tuberculosis in Beijing, 2016—2020 [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 164-168.
[13]	LIU Xin-yu, ZHANG Qian, SUN Qian. Analysis of drug resistance of multidrug-resistant Mycobacterium tuberculosis to multiple drugs in Changping District of Beijing [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(2): 169-173.
[14]	ZHANG Zhi-guo, GUO Hai-ping, PANG Yu. Considerations for the application of laboratory diagnostics in detecting drug-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 13-17.
[15]	WANG Zhi-hui, DONG Ya-kun, CHI Yue-peng, DI Hong-qin, LIANG Ya-chong, XIE Lan-pin. Evaluation of the application value of fluorescence PCR probe melting curve method in detecting drug resistance in elderly pulmonary tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2021, 2(1): 18-22.